In a report released yesterday, Naz Rahman from Maxim Group maintained a Buy rating on Quoin Pharmaceuticals (QNRX – Research Report), with a price target of $10.00. The company’s shares opened today at $1.50.
According to TipRanks, Rahman is an analyst with an average return of -34.1% and a 24.42% success rate. Rahman covers the Healthcare sector, focusing on stocks such as Agile Therapeutics, 9 Meters Biopharma, and Quoin Pharmaceuticals.
Quoin Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $11.00.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $64.38 and a one-year low of $1.50. Currently, Quoin Pharmaceuticals has an average volume of 460.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cellect Biotechnology Ltd. engages in the provision of regenerative medicine. Its activities include development of regenerative medicine through the development of products facilitating immune stem cell selection. The company also develops innovative technology, which allows the default stem cells by dramatically reducing of complications existing in conventional selection methods. Cellect Biotechnology was founded by Kasbian Nuriel Chirich, Shai Yarkoni and Nadir Askenasy on August 4, 1986 and is headquartered in Kfar Saba, Israel.
Read More on QNRX:
- Quoin Pharmaceuticals Announces Dosing of First Patient in Clinical Trial in Netherton Syndrome
- Quoin announces dosing of first patient in trial in Netherton Syndrome
- Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2022 Financial Results
- Quoin Pharmaceuticals reports Q3 ADS (94c) vs ($5.84) last year
- Quoin Pharmaceuticals to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 10th
